Dr Jorg Taubel attending ACCP in San Diego

Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.

Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad

Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London